Folks,
I am just looking into Bard so I have no preconceptions about the company or business.
Judging from the Development plan from Nov 19 am I right in the following statement?
1. Ovarian tests is well on its way.
2. Breast cancer testing is in the pipeline but hasn't really progressed
3. Lung Cancer is in the pipeline but isn't scheduled to be looked at until H2 2020.
Assuming that Breast cancer hasn't really progressed that far yet, would there be an opportunity to take advantage of current COVID19 situation and prioritise Lung Testing over Breast testing. Granted we are focused on cancer testing and that breast cancer is bigger issue than lung cancer.
With Silicosis on the rise would it not make sense to reverse the time frame of Breast vs Lung Testing?
Thoughts on BD1?, page-11
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $65.06M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 59.5¢ | 58.0¢ | $4.527K | 7.767K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38600 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |